Matthew R. Smith

10.4k total citations · 5 hit papers
72 papers, 5.4k citations indexed

About

Matthew R. Smith is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Matthew R. Smith has authored 72 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 28 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Matthew R. Smith's work include Prostate Cancer Treatment and Research (58 papers), Bone health and treatments (29 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Matthew R. Smith is often cited by papers focused on Prostate Cancer Treatment and Research (58 papers), Bone health and treatments (29 papers) and Radiopharmaceutical Chemistry and Applications (28 papers). Matthew R. Smith collaborates with scholars based in United States, France and Canada. Matthew R. Smith's co-authors include Karim Fizazi, Neal D. Shore, Carsten Goessl, Ronaldo Damião, Roger Dansey, Michael A. Carducci, Fred Saad, Philip W. Kantoff, Francis J. McGovern and Janet E. Brown and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Matthew R. Smith

68 papers receiving 5.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

2011 1.4k citations Karim Fizazi, Matthew R. Smith et al. profile →
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

2019 579 citations Karim Fizazi, Neal D. Shore et al. profile →
Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer

2002 520 citations Matthew R. Smith, Joel S. Finkelstein et al. The Journal of Clinical Endocrinology & Metabolism profile →
Pathologic fractures correlate with reduced survival in patients with malignant bone disease

2007 492 citations Fred Saad, Allan Lipton et al. Cancer profile →
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

2023 99 citations Maha Hussain, Bertrand Tombal et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Matthew R. Smith

Since Specialization

Citations

This map shows the geographic impact of Matthew R. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew R. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew R. Smith more than expected).

Fields of papers citing papers by Matthew R. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew R. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew R. Smith. The network helps show where Matthew R. Smith may publish in the future.

Co-authorship network of co-authors of Matthew R. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew R. Smith. A scholar is included among the top collaborators of Matthew R. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew R. Smith. Matthew R. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Detection of Venous Air Embolism in Nonsitting Craniotomy for Tumor Patients: A Retrospective Case Series 2025 ·Journal of Neurosurgical Anesthesiology ·Gabrielle A. White-Dzuro, Matthew R. Smith, (unknown), (unknown), Ariel Mueller, Timothy T. Houle, Oluwaseun Akeju, Brian V. Nahed, James Rhee	0
2	Windows in the ICU and Postoperative Delirium: A Retrospective Cohort Study 2025 ·Critical Care Medicine ·Diana C. Anderson, Petra Warner, Matthew R. Smith, (unknown), Ariel Mueller, (unknown), (unknown), Stacie Smith	0
3	Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial 2025 ·European Urology Oncology ·Joan Carles, Bertrand Tombal, Maha Hussain, Fred Saad, Karim Fizazi, Á. Montesa Pino, María José Méndez-Vidal, Alejo Rodríguez‐Vida, Daniel Castellano, Pablo Borrega, (unknown), (unknown), (unknown), Matthew R. Smith	0
4	New Paradigms for Bladder Cancer Management in Geriatrics 2025 ·Clinics in Geriatric Medicine ·(unknown), Matthew R. Smith, Kelly K. Bree	0
5	Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years 2015 ·Urologic Oncology Seminars and Original Investigations ·Mark A. Preston, Adam S. Feldman, John J. Coen, W. Scott McDougal, Matthew R. Smith, Jonathan J. Paly, Robert Carrasquillo, Chin‐Lee Wu, Douglas M. Dahl, Glen W. Barrisford, Michael L. Blute, Anthony Zietman	22
6	Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer 2013 ·European Urology ·Philip J. Saylor, Matthew R. Smith, A. James O’Malley, Nancy L. Keating	1
7	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial 2013 ·The Lancet Oncology ·Ethan Basch, Karen A. Autio, Charles J. Ryan, Peter Mulders, Neal D. Shore, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana E. Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas W. Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles S. Cleeland	114
8	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer 2012 ·Cancer Discovery ·David T. Miyamoto, Richard J. Lee, Shannon L. Stott, David T. Ting, Ben S. Wittner, Matthew Ulman, Malgorzata E. Smas, Jenna B. Lord, Brian W. Brannigan, Julie Trautwein, Neil H. Bander, Chin‐Lee Wu, Lecia V. Sequist, Matthew R. Smith, Sridhar Ramaswamy, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	217
9	Bone density testing among prostate cancer survivors treated with androgen‐deprivation therapy 2012 ·Cancer ·Alicia K. Morgans, Matthew R. Smith, A. James O’Malley, Nancy L. Keating	27
10	Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy 2011 ·Molecular Cancer Therapeutics ·Fadila Guessous, Yanzhi Yang, Elizabeth Johnson, Lukasz Marcinkiewicz, Matthew R. Smith, Ying Zhang, Alexander Kofman, David Schiff, James Christensen, Roger Abounader	19
11	Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer 2010 ·Clinical Genitourinary Cancer ·Richard J. Lee, Philip J. Saylor, Matthew R. Smith	17
12	The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors 2009 ·Journal of the National Comprehensive Cancer Network ·Allan Lipton, Robert G. Uzzo, Robert J. Amato, Georgiana K. Ellis, (unknown), G. David Roodman, Matthew R. Smith	87
13	Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02 2008 ·Journal of Clinical Oncology ·Matthew R. Smith, Kyounghwa Bae, Jason A. Efstathiou, Gerald E. Hanks, Miljenko V. Pilepich, Howard M. Sandler, William U. Shipley	47
14	Pathologic fractures correlate with reduced survival in patients with malignant bone disease breakdown → 2007 ·Cancer ·Fred Saad, Allan Lipton, Richard J. Cook, (unknown), Matthew R. Smith, Robert E. Coleman	492
15	Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy 2007 ·Psycho-Oncology ·William F. Pirl, Joseph A. Greer, (unknown), Matthew R. Smith	53
16	Future therapies in hormone-refractory prostate cancer 2005 ·Urology ·Matthew R. Smith, Joel B. Nelson	23
17	The role of bisphosphonates in the management of metastatic prostate cancer 2003 ·Current Oncology Reports ·M. Dror Michaelson, Matthew R. Smith	4
18	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up 2003 ·Urology ·William Oh, Judith Manola, (unknown), Adam Brufsky, Irving Kaplan, Matthew R. Smith, Donald S. Kaufman, Philip W. Kantoff	21
19	Measurement of body fat by dual-energy x-ray absorptiometry and bioimpedance analysis in men with prostate cancer 2002 ·Nutrition ·Matthew R. Smith, (unknown), Ellen J. Anderson, Mary Anne Fallon, Judith Manola	10
20	Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer breakdown → 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Matthew R. Smith, Joel S. Finkelstein, Francis J. McGovern, Anthony L. Zietman, Mary Anne Fallon, David Schoenfeld, Philip W. Kantoff	520

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact